BMS Faces Wider Criminal Probe Into Plavix Settlement

Washington Drug Letter
KEYWORDS courts / Rx
A A

Bristol-Myers Squibb’s (BMS) problems continue as the company lost substantial revenue from generic competition to its blood thinner Plavix and now faces potentially broader criminal charges related to the drug.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $10.00